Back to search

Article

Notable-HCC: A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early stage resectable hepatocellular carcinoma

2024-01-09

Abstract excerpt

<title>Abstract</title> <p>Background Hepatocellular carcinoma (HCC) is highly invasive, even for early stage HCC, the 1-year post-operative recurrence rates were over a quarter; so far no standard neoadjuvant therapy (NAT) is recommended by major guidelines. NAT with immune checkpoint inhibitors (ICIs) has been tried in varying solid tumors including HCC; radiotherapy showed immuno-modulating effect in the trea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f1319382-1eb9-514c-a8f8-216f902d3436
DOI
10.21203/rs.3.rs-3823003/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Notable-HCC: A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early stage resectable hepatocellular carcinomaDOI 10.21203/rs.3.rs-3823003/v1
Select a neighboring publication to make it the new centre.